Business Insider spoke to Eli Lilly's new president of cardiometabolic health, who shared the company's aggressive incretin ...

Discover why Novo Nordisk's current sell-off offers a strong buy opportunity. Backed by solid fundamentals, growth prospects, ...

Novo Nordisk had been providing Hims & Hers with the FDA-approved Wegovy used for weight loss since late April in order to ...

A simple oversight could end up costing Danish pharma giant Novo Nordisk A/S (NYSE: NVO) billions in potential losses on its blockbuster weight-loss and diabetes drug, Ozempic.

After ousting CEO, Novo Nordisk reclaims crown as largest European company Provided by Dow Jones Jun 13, 2025, 11:14:00 AM ...

The companies engaged in an increasingly heated war of words on Monday following the drugmaker's decision to end a collaboration.

Hims & Hers Health, Inc. (NYSE:HIMS) is one of the 10 Stocks Delivering Eye-Popping Gains. Hims & Hers rebounded by 11.76 ...

Hims & Hers Health (HIMS -3.91%) is a telehealth company that offers personalized solutions for its customers. And demand has ...

Hims & Hers Health Inc. won’t back down from selling cheap weight-loss shots, its chief executive officer said one day after Novo Nordisk A/S abruptly ended its distribution partnership.

Novo Nordisk's share price fell as well on Monday. However, the big pharma stock tumbled only around 5%, reflecting a much more muted impact on its business from scrapping the deal with Hims & Hers.